Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-151586 for Moderate to Severe Glabellar Lines in Japanese Subjects
NCT06151561Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trenibotulinumtoxinE in glabellar lines (4 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of participants with a >= 2-grade improvement from baseline on the Facial Wrinkle Scale with Asian (FWS-A) Guide at Day 7. Started Jan 2024; status: completed.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06151561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06151561.